-+ 0.00%
-+ 0.00%
-+ 0.00%

IceCure sees Q1 US ProSense revenue rise more than 30%

PUBT·04/21/2026 12:46:01
Listen to the news
IceCure sees Q1 US ProSense revenue rise more than 30%
  • IceCure projected Q1 2026 U.S. revenue from ProSense systems and cryoprobes rose more than 30% from Q1 2025, based on preliminary unaudited estimates.
  • U.S. sales momentum followed FDA clearance in October 2025 for ProSense use in local treatment of low-risk breast cancer in women aged 70 and above.
  • Installed base expansion continued at U.S. academic and research hospitals, supported by a pipeline expected to convert into new system sales in Q2 2026.
  • Massachusetts General Hospital cost analysis presented at SBI 2026 found cryoablation could cut total treatment costs by more than 50% versus breast-conserving surgery.
  • IceCure scheduled Q1 2026 operating and financial results release for May 14, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-045896), on April 21, 2026, and is solely responsible for the information contained therein.